March 22, 2018 / 8:38 PM / a month ago

BRIEF-Progenics Says FDA Will Extend Review Of NDA For Azedra By Three Months

March 22 (Reuters) - Progenics Pharmaceuticals Inc:

* PROGENICS PHARMACEUTICALS ANNOUNCES THREE-MONTH EXTENSION OF PDUFA DATE FOR AZEDRA (IOBENGUANE I 131)

* PROGENICS - FDA WILL EXTEND REVIEW OF NDA FOR AZEDRA (IOBENGUANE I 131) BY THREE MONTHS TO JULY 30, 2018​

* PROGENICS - ‍EXTENSION RESULT OF SUBMISSION OF ADDITIONAL CMC INFORMATION BY PROGENICS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below